Last reviewed · How we verify
Investigational aQIVc — Competitive Intelligence Brief
phase 3
Influenza vaccine (quadrivalent, cell-based)
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
Investigational aQIVc (Investigational aQIVc) — Seqirus. aQIVc is a cell-based quadrivalent influenza vaccine designed to provide broader and more durable immune protection against multiple influenza strains.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Investigational aQIVc TARGET | Investigational aQIVc | Seqirus | phase 3 | Influenza vaccine (quadrivalent, cell-based) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Influenza vaccine (quadrivalent, cell-based) class)
- Seqirus · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Investigational aQIVc CI watch — RSS
- Investigational aQIVc CI watch — Atom
- Investigational aQIVc CI watch — JSON
- Investigational aQIVc alone — RSS
- Whole Influenza vaccine (quadrivalent, cell-based) class — RSS
Cite this brief
Drug Landscape (2026). Investigational aQIVc — Competitive Intelligence Brief. https://druglandscape.com/ci/investigational-aqivc. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab